Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 120

1.

Artemether-lumefantrine treatment of uncomplicated Plasmodium falciparum malaria: a systematic review and meta-analysis of day 7 lumefantrine concentrations and therapeutic response using individual patient data.

WorldWide Antimalarial Resistance Network (WWARN) Lumefantrine PK/PD Study Group.

BMC Med. 2015 Sep 18;13:227. doi: 10.1186/s12916-015-0456-7. Review.

2.

Population Pharmacokinetics of Piperaquine in Young Ugandan Children Treated With Dihydroartemisinin-Piperaquine for Uncomplicated Malaria.

Sambol NC, Yan L, Creek DJ, McCormack SA, Arinaitwe E, Bigira V, Wanzira H, Kakuru A, Tappero JW, Lindegardh N, Tarning J, Nosten F, Aweeka FT, Parikh S.

Clin Pharmacol Ther. 2015 Jul;98(1):87-95. doi: 10.1002/cpt.104. Epub 2015 May 2.

PMID:
25732044
3.

Efficacy and day 7 plasma piperaquine concentrations in African children treated for uncomplicated malaria with dihydroartemisinin-piperaquine.

Zongo I, Somé FA, Somda SA, Parikh S, Rouamba N, Rosenthal PJ, Tarning J, Lindegardh N, Nosten F, Ouédraogo JB.

PLoS One. 2014 Aug 18;9(8):e103200. doi: 10.1371/journal.pone.0103200. eCollection 2014.

4.

Pharmacokinetics of co-formulated mefloquine and artesunate in pregnant and non-pregnant women with uncomplicated Plasmodium falciparum infection in Burkina Faso.

Valea I, Tinto H, Traore-Coulibaly M, Toe LC, Lindegardh N, Tarning J, Van Geertruyden JP, D'Alessandro U, Davies GR, Ward SA.

J Antimicrob Chemother. 2014 Sep;69(9):2499-507. doi: 10.1093/jac/dku154. Epub 2014 Jun 2.

5.

Benefits of a pharmacology antimalarial reference standard and proficiency testing program provided by the Worldwide Antimalarial Resistance Network (WWARN).

Lourens C, Lindegardh N, Barnes KI, Guerin PJ, Sibley CH, White NJ, Tarning J.

Antimicrob Agents Chemother. 2014 Jul;58(7):3889-94. doi: 10.1128/AAC.02362-14. Epub 2014 Apr 28.

6.

Preliminary pharmaceutical development of antimalarial-antibiotic cotherapy as a pre-referral paediatric treatment of fever in malaria endemic areas.

Gaubert A, Kauss T, Marchivie M, Ba BB, Lembege M, Fawaz F, Boiron JM, Lafarge X, Lindegardh N, Fabre JL, White NJ, Olliaro PL, Millet P, Grislain L, Gaudin K.

Int J Pharm. 2014 Jul 1;468(1-2):55-63. doi: 10.1016/j.ijpharm.2014.04.023. Epub 2014 Apr 13.

7.

Population pharmacokinetic assessment of the effect of food on piperaquine bioavailability in patients with uncomplicated malaria.

Tarning J, Lindegardh N, Lwin KM, Annerberg A, Kiricharoen L, Ashley E, White NJ, Nosten F, Day NP.

Antimicrob Agents Chemother. 2014;58(4):2052-8. doi: 10.1128/AAC.02318-13. Epub 2014 Jan 21.

8.

Disposition of amodiaquine and desethylamodiaquine in HIV-infected Nigerian subjects on nevirapine-containing antiretroviral therapy.

Scarsi KK, Fehintola FA, Ma Q, Aweeka FT, Darin KM, Morse GD, Akinola IT, Adedeji WA, Lindegardh N, Tarning J, Ojengbede O, Adewole IF, Taiwo B, Murphy RL, Akinyinka OO, Parikh S.

J Antimicrob Chemother. 2014 May;69(5):1370-6. doi: 10.1093/jac/dkt513. Epub 2014 Jan 19.

9.

Pharmacokinetics of orally administered oseltamivir in healthy obese and nonobese Thai subjects.

Jittamala P, Pukrittayakamee S, Tarning J, Lindegardh N, Hanpithakpong W, Taylor WR, Lawpoolsri S, Charunwattana P, Panapipat S, White NJ, Day NP.

Antimicrob Agents Chemother. 2014;58(3):1615-21. doi: 10.1128/AAC.01786-13. Epub 2013 Dec 23.

10.

Transient increase of interferon-stimulated genes and no clinical benefit by chloroquine treatment during acute simian immunodeficiency virus infection of macaques.

Vaccari M, Fenizia C, Ma ZM, Hryniewicz A, Boasso A, Doster MN, Miller CJ, Lindegardh N, Tarning J, Landay AL, Shearer GM, Franchini G.

AIDS Res Hum Retroviruses. 2014 Apr;30(4):355-62. doi: 10.1089/AID.2013.0218. Epub 2013 Dec 24.

11.

Population Pharmacokinetics of Lumefantrine in Pregnant and Nonpregnant Women With Uncomplicated Plasmodium falciparum Malaria in Uganda.

Kloprogge F, Piola P, Dhorda M, Muwanga S, Turyakira E, Apinan S, Lindegårdh N, Nosten F, Day NP, White NJ, Guerin PJ, Tarning J.

CPT Pharmacometrics Syst Pharmacol. 2013 Nov 13;2:e83. doi: 10.1038/psp.2013.59.

12.

Liquid chromatographic-mass spectrometric method for simultaneous determination of small organic acids potentially contributing to acidosis in severe malaria.

Sriboonvorakul N, Leepipatpiboon N, Dondorp AM, Pouplin T, White NJ, Tarning J, Lindegardh N.

J Chromatogr B Analyt Technol Biomed Life Sci. 2013 Dec 15;941:116-22. doi: 10.1016/j.jchromb.2013.10.005. Epub 2013 Oct 16.

13.
14.

Reduced susceptibility of Plasmodium falciparum to artesunate in southern Myanmar.

Kyaw MP, Nyunt MH, Chit K, Aye MM, Aye KH, Aye MM, Lindegardh N, Tarning J, Imwong M, Jacob CG, Rasmussen C, Perin J, Ringwald P, Nyunt MM.

PLoS One. 2013;8(3):e57689. doi: 10.1371/journal.pone.0057689. Epub 2013 Mar 8.

15.

Population pharmacokinetics of intramuscular artesunate in African children with severe malaria: implications for a practical dosing regimen.

Hendriksen IC, Mtove G, Kent A, Gesase S, Reyburn H, Lemnge MM, Lindegardh N, Day NP, von Seidlein L, White NJ, Dondorp AM, Tarning J.

Clin Pharmacol Ther. 2013 May;93(5):443-50. doi: 10.1038/clpt.2013.26. Epub 2013 Feb 8.

16.

Comparison of oseltamivir and oseltamivir carboxylate concentrations in venous plasma, venous blood, and capillary blood in healthy volunteers.

Instiaty I, Lindegardh N, Jittmala P, Hanpithakpong W, Blessborn D, Pukrittayakamee S, White NJ, Tarning J.

Antimicrob Agents Chemother. 2013 Jun;57(6):2858-62. doi: 10.1128/AAC.02408-12. Epub 2013 Mar 18.

17.

Pharmacokinetic predictors for recurrent malaria after dihydroartemisinin-piperaquine treatment of uncomplicated malaria in Ugandan infants.

Creek DJ, Bigira V, McCormack S, Arinaitwe E, Wanzira H, Kakuru A, Tappero JW, Sandison TG, Lindegardh N, Nosten F, Aweeka FT, Parikh S.

J Infect Dis. 2013 Jun 1;207(11):1646-54. doi: 10.1093/infdis/jit078. Epub 2013 Feb 27.

18.

Pharmacokinetic properties of anti-influenza neuraminidase inhibitors.

Chairat K, Tarning J, White NJ, Lindegardh N.

J Clin Pharmacol. 2013 Feb;53(2):119-39. doi: 10.1177/0091270012440280. Epub 2013 Jan 24. Review.

PMID:
23436258
19.

Combination therapy with amantadine, oseltamivir and ribavirin for influenza A infection: safety and pharmacokinetics.

Seo S, Englund JA, Nguyen JT, Pukrittayakamee S, Lindegardh N, Tarning J, Tambyah PA, Renaud C, Went GT, de Jong MD, Boeckh MJ.

Antivir Ther. 2013;18(3):377-86. doi: 10.3851/IMP2475. Epub 2012 Dec 21.

20.

Pharmaceutical development and optimization of azithromycin suppository for paediatric use.

Kauss T, Gaubert A, Boyer C, Ba BB, Manse M, Massip S, Léger JM, Fawaz F, Lembege M, Boiron JM, Lafarge X, Lindegardh N, White NJ, Olliaro P, Millet P, Gaudin K.

Int J Pharm. 2013 Jan 30;441(1-2):218-26. doi: 10.1016/j.ijpharm.2012.11.040. Epub 2012 Dec 3.

Items per page

Supplemental Content

Loading ...
Write to the Help Desk